Spruce Street Capital LP Invests $34.59 Million in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 354,816 shares of the company's stock, valued at approximately $34,587,464. Dianthus Therapeutics makes up about 0.0% of Spruce Street Capital LP's portfolio, making the stock its 6th largest position. Spruce Street Capital LP owned 0.65% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company's stock valued at $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Virtus Investment Advisers LLC increased its holdings in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company's stock valued at $260,000 after purchasing an additional 416 shares during the last quarter. Royal Bank of Canada boosted its stake in Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company's stock valued at $82,000 after buying an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wolfe Research restated an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. HC Wainwright increased their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $124.27.

Insider Activity at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares of the company's stock, valued at $7,058,718.12. The trade was a 71.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Adam M. Veness sold 16,167 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the transaction, the senior vice president owned 3,833 shares in the company, valued at $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 287,084 shares of company stock worth $29,615,923 in the last quarter. 3.02% of the stock is owned by insiders.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded down $5.04 during midday trading on Friday, hitting $106.50. 182,209 shares of the company traded hands, compared to its average volume of 941,019. Dianthus Therapeutics, Inc. has a 12 month low of $22.81 and a 12 month high of $117.88. The firm's fifty day moving average price is $103.13 and its 200-day moving average price is $86.95. The stock has a market cap of $5.82 billion, a price-to-earnings ratio of -25.66 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source